The EU butts heads with Big Pharma to make medicines cheaper

By HEOR Staff Writer

February 2, 2023

The new EU proposal to revamp its pharmaceutical regulations. The main aim is to give people a better and more affordable access to medicines.

From what I can see, there are mixed feelings about the proposal. On one hand, consumer groups and civil society organizations are applauding the EU’s efforts to make medicines more accessible. On the other hand, the pharmaceutical industry is a bit skeptical.

So, what’s in the proposal? Well, the EU is looking to shorten the period in which pharmaceutical companies can sell their medicines without competition from 10 years to just 8 years. They’re also working towards closing the gap in access to medicines among different EU member states.

It’s interesting to see how this will all play out. What are your thoughts on the EU Pharmaceutical Regulations Proposal?

Reference url

Recent Posts

Null Link Confirmed: Prenatal Acetaminophen Autism Risk Study in Denmark

By HEOR Staff Writer

April 17, 2026

A major nationwide Danish cohort study has found no link between maternal acetaminophen use during pregnancy and autism in children. The new evidence on prenatal acetaminophen autism risk should reassure clinicians and expectant mothers, as both population-wide and sibling-controlled analyses sho...
Amyloid-Beta Treatment Impact: Limited Clinical Benefits and Increased Risks in Early Alzheimer’s...

By HEOR Staff Writer

Amyloid-Beta Treatment Impact on people with early Alzheimer’s disease is minimal, according to a major new Cochrane review. The analysis of 17 randomized controlled trials involving more than 20,000 participants found that amyloid-beta-targeting monoclonal antibodies deliver only trivial improve...
Escalating Public Spending: Semaglutide Off-Label Use Sparks €250 Million Fraud Investigation in ...

By João L. Carapinha

Semaglutide off-label use for weight loss is at the centre of a suspected €250 million fraud uncovered by Portugal’s Judicial Police within the National Health Service (SNS). According to the investigation reported on 15 April 2026, roughly half of all public spending on Ozempic (semaglutide) bet...